2-Aminothiazolones as Anti-HIV Agents That Act as gp120-CD4 Inhibitors | Zendy

Marika Tiberi | Zendy; Cristina Tintori | Zendy; Elisa Rita Ceresola | Zendy; Roberta Fazi | Zendy; Claudio Zamperini | Zendy; Pierpaolo Calandro | Zendy; Luigi Franchi | Zendy; Manikandan Selvaraj | Zendy; Lorenzo Botta | Zendy; Michela Sampaolo | Zendy; Diego Saita | Zendy; Roberto Ferrarese | Zendy; Massimo Clementi | Zendy; Filippo Canducci | Zendy; Maurizio Botta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

2-Aminothiazolones as Anti-HIV Agents That Act as gp120-CD4 Inhibitors

Author(s) -

Marika Tiberi,

Cristina Tintori,

Elisa Rita Ceresola,

Roberta Fazi,

Claudio Zamperini,

Pierpaolo Calandro,

Luigi Franchi,

Manikandan Selvaraj,

Lorenzo Botta,

Michela Sampaolo,

Diego Saita,

Roberto Ferrarese,

Massimo Clementi,

Filippo Canducci,

Maurizio Botta

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02739-13

Subject(s) - adme , docking (animal) , human immunodeficiency virus (hiv) , cytotoxicity , chemistry , pharmacology , biology , computational biology , drug , virology , biochemistry , in vitro , medicine , nursing

We report here the synthesis of 2-aminothiazolones along with their biological properties as novel anti-HIV agents. Such compounds have proven to act through the inhibition of the gp120-CD4 protein-protein interaction that occurs at the very early stage of the HIV-1 entry process. No cytotoxicity was found for these compounds, and broad antiviral activities against laboratory strains and pseudotyped viruses were documented. Docking simulations have also been applied to predict the mechanism, at the molecular level, by which the inhibitors were able to interact within the Phe43 cavity of HIV-1 gp120. Furthermore, a preliminary absorption, distribution, metabolism, and excretion (ADME) evaluation was performed. Overall, this study led the basis for the development of more potent HIV entry inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research